Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True?

被引：16
|
作者：
Kaul, Sanjay [1 ]
机构：
[1] Cedars Sinai Med Ctr, Div Cardiol, 8635 W Third St,Ste 790W, Los Angeles, CA 90048 USA
来源：
CIRCULATION | 2016年 / 134卷 / 02期
关键词：
clinical trial; diabetes mellitus; mortality; TRIAL;
D O I：
10.1161/CIRCULATIONAHA.116.022537
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：94 / +
页数：11
相关论文
共 50 条
  • [41] Utilization of Empagliflozin in Patients with Type 2 Diabetes Mellitus and Congestive Heart Failure
    Alvarez, Carlos A.
    Perkins, Aaron
    Sigler, Meredith A.
    Yang, Hui
    Caberwal, Harjeet
    Ebrahimi, Ramin
    [J]. DIABETES, 2023, 72
  • [42] Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease
    Anker, Stefan D.
    Sander, Leif-Erik
    Fitchett, David H.
    Zinman, Bernard
    Ofstad, Anne Pernille
    Wanner, Christoph
    Vedin, Ola
    Lauer, Sabine
    Verma, Subodh
    Yaggi, Henry K.
    Inzucchi, Silvio E.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [43] Pilot study in pharmacogenomic management of empagliflozin in type 2 diabetes mellitus patients
    Mahdieh Jamalizadeh
    Mandana Hasanzad
    Negar Sarhangi
    Farshad Sharifi
    Ensieh Nasli-Esfahani
    Bagher Larijani
    [J]. Journal of Diabetes & Metabolic Disorders, 2021, 20 : 1407 - 1413
  • [44] Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus
    Triplitt, C.
    Solis-Herrera, C.
    Cersosimo, E.
    Abdul-Ghani, M.
    Defronzo, Ralph A.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (18) : 2819 - 2833
  • [45] Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus
    Salukhov, Vladimir V.
    Demidova, Tatiana Y.
    [J]. DIABETES MELLITUS, 2016, 19 (06): : 494 - 510
  • [46] ?Not Too Good to be True?: A Proposal to Further Benefit from Emergence in Management Research
    Adrot, Anouck
    [J]. MANAGEMENT, 2023, 26 (01): : 85 - 94
  • [47] Benefit of mechanical ventilation during neonatal cardiopulmonary bypass: too good to be true?
    Karl, Tom R.
    [J]. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2022, 61 (06) : 1289 - 1289
  • [48] Is Relative Mortality of Type 2 Diabetes Mellitus Decreasing?
    Gulliford, Martin C.
    Charlton, Judith
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2009, 169 (04) : 455 - 461
  • [49] Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease
    Fitchett, David
    Inzucchi, Silvio E.
    Lachin, John M.
    Wanner, Christoph
    van de Borne, Philippe
    Mattheus, Michaela
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    George, Jyothis T.
    Zinman, Bernard
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (03) : 364 - 367
  • [50] In type 2 diabetes with CVD and kidney disease, empagliflozin reduced mortality and hospitalization
    Moist, Louise
    [J]. ANNALS OF INTERNAL MEDICINE, 2018, 168 (10) : JC52 - JC52
12345